Table 1.
Patients detailsa
| Case no. | Gender, age (yr) | Disease duration (yr) | UPDRS III (OFF) | UPDRS III (ON) | Predominant symptom(s) | Medication (daily doses) |
|---|---|---|---|---|---|---|
| 1 | F, 65 | 5 | 33 | 11 | Bradykinesia, | Levodopa, 300 mg |
| tremor | Amantadine, 200 mg | |||||
| Rasagiline, 1 mg | ||||||
| 2 | F, 68 | 14 | 28 | 15 | Bradykinesia, rigidity | Levodopa, 200 mg |
| Ropinirole, 18 mg | ||||||
| Rasagiline 1 mg | ||||||
| 3 | M, 68 | 13 | 42 | 24 | Bradykinesia, rigidity, freezing | Levodopa, 500 mg |
| Amantadine,100 mg | ||||||
| Ropinirole, 24 mg | ||||||
| 4b | M, 59 | 7 | 61 | 9 | Bradykinesia, rigidity, freezing | Levodopa, 600–1100 mg Ropinirole,12 mg |
| 5 | F, 59 | 14 | 61 | 27 | Dyskinesia, | Levodopa, 750 mg |
| prolonged OFF periods | Selegiline,1.25 mg | |||||
| 6 | M, 59 | 8 | 49 | 25 | Dyskinesia, freezing, | Levodopa, 850 mg |
| prolonged OFF periods | Amantadine,100 mg Entacapone,1000 mg | |||||
| Ropinirole,10 mg | ||||||
| Rasagiline,1 mg | ||||||
| 7 | M, 62 | 11 | 63 | 38 | Tremor, bradykinesia, rigidity | Levodopa, 500 mg |
| Ropinirole 24 mg | ||||||
| 8 | M, 69 | 9 | 53 | 26 | Rigidity, bradykinesia | Levodopa, 375 mg |
| Entacapone, 800 mg | ||||||
| Ropinirole, 2 mg | ||||||
| 9 | F, 66 | 17 | 25 | 14 | Freezing, falls | Levodopa, 375 mg |
| Entacapone, 1000 mg | ||||||
| Amantadine, 200 mg | ||||||
| Ropinirole, 16 mg | ||||||
| 10 | M, 70 | 11 | NA | NA | Tremor | Levodopa, 600 mg |
| Entacapone, 1000 mg | ||||||
| Rotigotine, 4 mg | ||||||
| 11 | F, 56 | 9 | 49 | 29 | Dystonia, bradykinesia, rigidity | Levodopa, 50 mg |
| Apomorphine, 5 mg/h | ||||||
| Rasagiline, 1 mg | ||||||
| 12 | M, 65 | 6 | NA | NA | Tremor | Levodopa, 650 mg |
| Rasagiline, 1 mg | ||||||
| Ropinirole, 21 mg |
aUPDRS (III), Part III motor score of the Unified Parkinson's Disease Rating Scale; NA, missing data. All patients had bilateral implantations.
bIn Subject 4, no signal was recorded for 2 contacts of the right electrode (R3/R4).